Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Parenthetical) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Total net revenue		$ 96,169	$ 102,562	$ 319,886	$ 285,353
Total cost of revenue	[1]	61,385	63,020	202,951	169,577
Research and development	[2]	14,104	13,268	43,183	37,372
Products
Total net revenue	[3]	43,198	47,439	156,678	120,502
Total cost of revenue		28,371	27,709	95,400	69,237
Services
Total net revenue	[4]	52,971	55,123	163,208	164,851
Total cost of revenue		33,014	35,311	107,551	100,340
Revenue from Joint Venture
Total cost of revenue		14,838	2,387	29,086	7,088
Research and development		549	0	1,543	430
Revenue from Joint Venture | Products
Total net revenue		17,442	1,633	32,177	5,954
Revenue from Joint Venture | Services
Total net revenue		$ 2,326	$ 4,934	$ 7,820	$ 10,197

[1] Includes cost of revenue from sales to the China joint venture, an equity method investment of $14,838 and $29,086 for the three and nine months ended March 31, 2022 and $2,387 and $7,088 for the three and nine months ended March 31, 2021, respectively.

[2] Includes chargeback to the China joint venture, an equity method investment related to research and development project of $549 and $1,543 for the three and nine months ended March 31, 2022 $0 and $430 for the three and nine months ended March 31, 2021.

[3] Includes sales to the China joint venture, an equity method investment of $17,442 and $32,177 for the three and nine months ended March 31, 2022 and $1,633 and $5,954 for the three and nine months ended March 31, 2021, respectively. See Note 14.

[4] Includes sales to the China joint venture, an equity method investment of $2,326 and $7,820 for the three and nine months ended March 31, 2022 and $4,934 and $10,197 for the three and nine months ended March 31, 2021, respectively. See Note 14.